Evoking plasmin for β-amyloid clearance

Cell Research

Volumn 18, Issue 8, 2008, Pages 803-804

  Zhao, Jian ^a   Pei, Gang ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ENZYME INHIBITOR; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; ANIMAL; BRAIN; DRUG DESIGN; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 49149083787     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.89     Document Type: Short Survey

References (11)

1. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314:777-781.
2. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001; 3:75-80.
3. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8:663-672.
4. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44:181-193.
5. Postina R. A closer look at alpha-secretase. Curr Alzheimer Res 2008; 5:179-186.
6. Nathalie P, Jean-Noel O. Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Curr Alzheimer Res 2008; 5:92-99.
7. Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 2008; 5:225-231.
8. McDermott JR, Gibson AM. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res 1997; 22:49-56.
9. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008; 5:212-224.
10. Jacobsen JS, Comery TA, Martone RL, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci USA 2008; 105:8754-8759.
11. Dotti CG, Galvan C, Ledesma MD. Plasmin deficiency in Alzheimer's disease brains: causal or casual? Neurodegener Dis 2004; 1:205-212.